Natco spurts on FDA nod for Prevacid copy but crowded market awaits
This article was originally published in Scrip
Executive Summary
Shares of Natco Pharma spurted on Indian stock exchanges after the company announced that the US FDA had approved its ANDA for lansoprazole delayed release capsules 15mg and 30mg, generic versions of Takeda’s proton pump inhibitor, Prevacid.